RESUMO
BACKGROUND: Endoscopic resection can be used for removing colloid cysts as a substitute for open craniotomy. Cerebral vasospasm, a possible complication of the craniotomy procedure, has not been reported as a complication of endoscopic removal of colloid cysts. CASE DESCRIPTION: A 58-year-old man developed the worst headache of his life. The CT and MRI showed a 1.3 cm midline third ventricular cyst at the level of the foramen of Monro, consistent with a colloid cyst. The patient elected to undergo an endoscopic resection of the colloid cyst. The image-guided frameless stereotactic endoscopic colloid cyst resection proceeded without events. Postoperative MRI showed a gross total resection. The patient continued to improve until post-operative day #9 when he experienced an episode of slurred speech and several episodes of legs buckling. An MRI did not show a stroke. A CT angiogram showed diffuse vasospasm, including the basilar artery and bilateral middle cerebral arteries, when compared to the patient's preoperative MRA. The patient's antihypertensive medications were stopped. The patient was started on Nimodipine, 60 mg every 4 hours, and triple H therapy (Hypertension, Hypervolemia, and Hemodilution) was applied. His blood pressure rose and his neurologic exam improved over several days. The patient returned to his baseline in 14 days without any neurological deficits. To our knowledge, this is the first case report of a patient undergoing endoscopic colloid cyst resection that was complicated by diffuse cerebral vasospasm. CONCLUSIONS: We report the first case of acute, transient cerebral vasospasm following endoscopic resection of a colloid cyst.
Assuntos
Cistos Coloides , Terceiro Ventrículo , Vasoespasmo Intracraniano , Masculino , Humanos , Pessoa de Meia-Idade , Cistos Coloides/diagnóstico por imagem , Cistos Coloides/cirurgia , Cistos Coloides/complicações , Vasoespasmo Intracraniano/diagnóstico por imagem , Vasoespasmo Intracraniano/etiologia , Endoscopia/métodos , Terceiro Ventrículo/cirurgia , Procedimentos Neurocirúrgicos/métodosRESUMO
BACKGROUND: Fatigue is a common and disabling symptom in people with a primary brain tumour (PBT). The effectiveness of interventions for treating clinically significant levels of fatigue in this population is unclear. This is an updated version of the original Cochrane Review published in Issue 4, 2016. OBJECTIVES: To assess the effectiveness and safety of pharmacological and non-pharmacological interventions for adults with PBT and clinically significant (or high levels) of fatigue. SEARCH METHODS: For this updated review, we searched CENTRAL, MEDLINE and Embase, and checked the reference lists of included studies in April 2022. We also searched relevant conference proceedings, and ClinicalTrials.gov for ongoing trials. SELECTION CRITERIA: We included randomised controlled trials (RCTs) that investigated any pharmacological or non-pharmacological intervention in adults with PBT and fatigue, where fatigue was the primary outcome measure. We restricted inclusion specifically to studies that enrolled only participants with clinically significant levels of fatigue to improve the clinical utility of the findings. DATA COLLECTION AND ANALYSIS: Two review authors (JD, DC) independently evaluated search results for the updated search. Two review authors (JD, SYK) extracted data from selected studies, and carried out a risk of bias assessment. We extracted data on fatigue, mood, cognition, quality of life and adverse events outcomes. MAIN RESULTS: The original review identified one study and this update identified a further two for inclusion. One study investigated the use of modafinil, one study the use of armodafinil and one study the use of dexamfetamine. We identified three ongoing studies. In the original review, the single eligible trial compared modafinil to placebo for 37 participants with a high- or low-grade PBT. One new study compared two doses of armodafinil (150 mg and 250 mg) to placebo for 297 people with a high-grade glioma. The second new study compared dexamfetamine sulfate to placebo for 46 participants with a low- or high-grade PBT. The evidence was uncertain for both modafinil and dexamfetamine regarding fatigue outcome measures, compared to controls, at study endpoint. Two trials did not reach the planned recruitment target and therefore may not, in practice, have been adequately powered to detect a difference. These trials were at a low risk of bias across most areas. There was an unclear risk of bias related to the use of mean imputation for one study because the investigators did not analyse the impact of imputation on the results and information regarding baseline characteristics and randomisation were not clear. The certainty of the evidence measured using GRADE was very low across all three studies. There was one identified study awaiting classification once data are available, which investigated the feasibility of 'health coaching' for people with a PBT experiencing fatigue. There were three ongoing studies that may be eligible for an update of this review, all investigating a non-pharmacological intervention for fatigue in people with PBT. AUTHORS' CONCLUSIONS: There is currently insufficient evidence to draw reliable and generalisable conclusions regarding potential effectiveness or harm of any pharmacological or non-pharmacological treatments for fatigue in people with PBT. More research is needed on how best to treat people with brain tumours with high fatigue.
Assuntos
Neoplasias Encefálicas , Glioma , Adulto , Neoplasias Encefálicas/complicações , Dextroanfetamina/uso terapêutico , Fadiga/etiologia , Fadiga/terapia , Humanos , Modafinila/uso terapêuticoAssuntos
Encefalopatias , COVID-19 , Teorema de Bayes , Estudos de Casos e Controles , Humanos , Morbidade , SARS-CoV-2RESUMO
Patients with primary brain tumors often experience seizures, which can be the presenting symptom or occur for the first time at any point along the illness trajectory. In addition to causing morbidity, seizures negatively affect independence and quality of life in other ways, for example, by leading to loss of driving privileges. Long-term therapy with antiepileptic drugs (AEDs) is the standard of care in brain tumor patients with seizures, but the role of prophylactic AEDs in seizure-naive patients remains controversial. In this article, experts in the field discuss the issues of AED efficacy and toxicity, and explain their differing recommendations for routine use of prophylactic AEDs.
Assuntos
Neoplasias Encefálicas/diagnóstico por imagem , Imageamento por Ressonância Magnética/métodos , Necrose/etiologia , Recidiva Local de Neoplasia/complicações , Tomografia por Emissão de Pósitrons/métodos , Lesões por Radiação/etiologia , Radiocirurgia/métodos , Idoso , Neoplasias Encefálicas/secundário , Feminino , HumanosRESUMO
BACKGROUND: Lidocaine, mexiletine, tocainide, and flecainide are local anesthetics which give an analgesic effect when administered orally or parenterally. Early reports described the use of intravenous lidocaine or procaine to relieve cancer and postoperative pain. Interest reappeared decades later when patient series and clinical trials reported that parenteral lidocaine and its oral analogs tocainide, mexiletine, and flecainide relieved neuropathic pain in some patients. With the recent publication of clinical trials with high quality standards, we have reviewed the use of systemic lidocaine and its oral analogs in neuropathic pain to update our knowledge, to measure their benefit and harm, and to better define their role in therapy. OBJECTIVES: To evaluate pain relief and adverse effect rates between systemic local anesthetic-type drugs and other control interventions. SEARCH METHODS: We searched MEDLINE (1966 through 15 May 2004), EMBASE (January 1980 to December 2002), Cancer Lit (through 15 December 2002), Cochrane Central Register of Controlled Trials (2nd Quarter, 2004), System for Information on Grey Literature in Europe (SIGLE), and LILACS, from January 1966 through March 2001. We also hand searched conference proceedings, textbooks, original articles and reviews. SELECTION CRITERIA: We included trials with random allocation, that were double blinded, with a parallel or crossover design. The control intervention was a placebo or an analgesic drug for neuropathic pain from any cause. DATA COLLECTION AND ANALYSIS: We collected efficacy and safety data from all published and unpublished trials. We calculated combined effect sizes using continuous and binary data for pain relief and adverse effects as primary and secondary outcome measurements, respectively. MAIN RESULTS: Thirty-two controlled clinical trials met the selection criteria; two were duplicate articles. The treatment drugs were intravenous lidocaine (16 trials), mexiletine (12 trials), lidocaine plus mexiletine sequentially (one trial), and tocainide (one trial). Twenty-one trials were crossover studies, and nine were parallel. Lidocaine and mexiletine were superior to placebo [weighted mean difference (WMD) = -11; 95% CI: -15 to -7; P < 0.00001], and limited data showed no difference in efficacy (WMD = -0.6; 95% CI: -7 to 6), or adverse effects versus carbamazepine, amantadine, gabapentin or morphine. In these trials, systemic local anesthetics were safe, with no deaths or life-threatening toxicities. Sensitivity analysis identified data distribution in three trials as a probable source of heterogeneity. There was no publication bias. AUTHORS' CONCLUSIONS: Lidocaine and oral analogs were safe drugs in controlled clinical trials for neuropathic pain, were better than placebo, and were as effective as other analgesics. Future trials should enroll specific diseases and test novel lidocaine analogs with better toxicity profiles. More emphasis is necessary on outcomes measuring patient satisfaction to assess if statistically significant pain relief is clinically meaningful.
CONTEXTE: La lidocaïne, le mexilétine, la tocainide et la flécainide sont des anesthésiques locaux qui apportent un effet analgésique lorsqu'ils sont administrés par voie orale ou parentérale. Des études anciennes décrivaient l'utilisation de lidocaïne ou de procaïne par voie intraveineuse pour soulager la douleur due au cancer ou la douleur postopératoire. Un regain d'intérêt a eu lieu quelques décennies plus tard lorsque des séries de patients et des essais cliniques ont rapporté que la lidocaïne par voie parentérale ou ses analogues oraux, tocainide, méxiléine et flécainide, soulageaient la douleur neuropathique chez certains patients. Avec la publication récente d'essais cliniques suivant des normes de qualité, nous avons révisé l'utilisation de lidocaïne systémique et de ses analogues oraux en douleur neuropathique pour mettre à jour nos connaissances, mesurer leurs bénéfices et effets délétères et mieux définir leur rôle dans le traitement. OBJECTIFS: Évaluer le soulagement de la douleur et les effets indésirables entre les médicaments de type anesthésique local systémique et d'autres interventions de contrôle. STRATÉGIE DE RECHERCHE DOCUMENTAIRE: Nous avons effectué une recherche dans MEDLINE (de 1966 au 15 mai 2004), EMBASE (de janvier 1980 à décembre 2002), Cancer Lit (jusqu'au 15 décembre 2002), le registre Cochrane des essais contrôlés (2ème trimestre 2004),le Système pour l'Information en Littérature Grise en Europe (SIGLE), et LILACS, de janvier 1966 à mars 2001. Nous avons également recherché des actes de conférences, des ouvrages, des articles originaux et des revues. CRITÈRES DE SÉLECTION: Nous avons inclus des essais à assignation aléatoire, en double aveugle, avec un plan d'étude parallèle ou croisé. L'intervention de contrôlé était un placebo ou un médicament analgésique contre la douleur neuropathique quelle qu'en soit la cause. RECUEIL ET ANALYSE DES DONNÉES: Nous avons recueilli des données sur l'efficacité et la sécurité à partir de tous les essais publiés et non publiés. Nous avons calculé les quantités d'effet combinées en utilisant les données continues et binaires pour le soulagement de la douleur et les effets indésirables en tant que critères de jugement principal et secondaire, respectivement. RÉSULTATS PRINCIPAUX: Trentedeux essais cliniques contrôlés satisfaisaient aux critères de sélection ; deux d'entre eux étaient des articles en double. Les médicaments de traitement étaient la lidocaïne intraveineuse (16 essais), la mexilétine (12 essais), la lidocaïne plus la mexilétine séquentiellement (un essai) et la tocainide (un essai). Vingtetun essais étaient des études croisées et neuf étaient des études parallèles. La lidocaïne et la mexilétine se sont avérées supérieures au placebo [différence moyenne pondérée (DMP) = 11 ; IC à 95 % : 15 à 7 ; P < 0,00001], et des données limitées n'ont mis en évidence aucune différence de l'efficacité (DMP = 0,6 ; IC à 95 % : 7 à 6) ou des événements indésirables versus carbamazépine, amantadine, gabapentine ou morphine. Dans ces essais, les anesthésiques locaux systémiques étaient sûrs, avec la non occurrence de toxicités mortelles ou dangereuses. L'analyse de la sensibilité a permis d'identifier la distribution des données dans trois essais comme étant une source probable d'hétérogénéité. Aucun biais de publication n'a été observé. CONCLUSIONS DES AUTEURS: Ces essais cliniques contrôlés sur la douleur neuropathique ont permis de déterminer qu la lidocaïne et ses analogues oraux sont des médicaments sûrs, plus efficaces que le placebo et aussi efficaces que d'autres analgésiques. Les prochains essais devraient porter sur des maladies spécifiques et tester de nouveaux analogues de la lidocaïne avec de meilleurs profils de toxicité. Il est nécessaire de se centrer plus particulièrement sur les résultats mesurant la satisfaction des patients pour déterminer si le soulagement de la douleur significatif du point de vue statistique est pertinent cliniquement.
Assuntos
Anestesia Local , Anestésicos Locais/administração & dosagem , Neuralgia/tratamento farmacológico , Administração Cutânea , Humanos , Ensaios Clínicos Controlados Aleatórios como Assunto , Resultado do TratamentoRESUMO
BACKGROUND: Repurposed memantine, mefloquine, and metformin have putative anticancer activity. The objective of this phase 1 study was to determine the maximum tolerated doses (MTDs) of combinations of these agents with temozolomide (TMZ). METHODS: Adults with newly diagnosed glioblastoma who completed chemoradiation were eligible. The patients were assigned to receive doublet, triplet, or quadruplet therapy with TMZ combined with mefloquine, memantine, and/or metformin. Dose-limiting toxicities (DLTs) were determined, using a 3 + 3 study design. RESULTS: Of 85 enrolled patients, 4 did not complete cycle 1 (the DLT observation period) for nontoxicity reasons, and 81 were evaluable for DLT. The MTDs for doublet therapy were memantine 20 mg twice daily, mefloquine 250 mg 3 times weekly, and metformin 850 mg twice daily. For triplet therapy, the MTDs were memantine 10 mg twice daily, mefloquine 250 mg 3 times weekly, and metformin 850 mg twice daily. For quadruplet therapy, the MTDs were memantine 10 mg twice daily, mefloquine 250 mg 3 times weekly, and metformin 500 mg twice daily. DLTs included dizziness (memantine) and gastrointestinal effects (metformin). Lymphopenia was the most common adverse event (66%). From study entry, the median survival was 21 months, and the 2-year survival rate was 43%. CONCLUSIONS: Memantine, mefloquine, and metformin can be combined safely with TMZ in patients with newly diagnosed glioblastoma.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Neoplasias Encefálicas , Glioblastoma , Mefloquina/administração & dosagem , Memantina/administração & dosagem , Metformina/administração & dosagem , Temozolomida/administração & dosagem , Adulto , Idoso , Neoplasias Encefálicas/diagnóstico , Neoplasias Encefálicas/tratamento farmacológico , Neoplasias Encefálicas/patologia , Neoplasias Encefálicas/radioterapia , Quimioterapia Adjuvante , Ensaios Clínicos Fase II como Assunto/métodos , Feminino , Glioblastoma/diagnóstico , Glioblastoma/tratamento farmacológico , Glioblastoma/patologia , Glioblastoma/radioterapia , Humanos , Masculino , Dose Máxima Tolerável , Mefloquina/efeitos adversos , Memantina/efeitos adversos , Metformina/efeitos adversos , Pessoa de Meia-Idade , Intervalo Livre de Progressão , Radioterapia Adjuvante , Projetos de Pesquisa , Temozolomida/efeitos adversos , Resultado do Tratamento , Adulto JovemRESUMO
Glioblastoma (GBM) is the most common type of malignant tumor found in the brain, and acts very aggressively by quickly and diffusely infiltrating the surrounding brain parenchyma. Despite its aggressive nature, GBM is rarely found to spread extracranially and develop distant metastases. The most common sites of these rare metastases are the lungs, pleura and cervical lymph nodes. There are also a few case reports of skin metastasis. We present the clinical, imaging and pathologic features of a case of a GBM with metastasis to the soft tissue scar and skin near the original craniotomy site. In addition, we discuss the details of this case in the context of the previously reported literature.
Assuntos
Anti-Infecciosos/efeitos adversos , Ansiedade/induzido quimicamente , Neoplasias Encefálicas/terapia , Quimiorradioterapia , Cianose/induzido quimicamente , Dapsona/efeitos adversos , Edema/induzido quimicamente , Glioblastoma/terapia , Infecções Oportunistas/prevenção & controle , Pneumonia por Pneumocystis/prevenção & controle , Ansiedade/diagnóstico , Ansiedade/terapia , Neoplasias Encefálicas/imunologia , Neoplasias Encefálicas/patologia , Quimiorradioterapia/efeitos adversos , Cianose/diagnóstico , Cianose/terapia , Edema/diagnóstico , Edema/terapia , Feminino , Glioblastoma/imunologia , Glioblastoma/patologia , Humanos , Hospedeiro Imunocomprometido , Pessoa de Meia-Idade , Infecções Oportunistas/imunologia , Infecções Oportunistas/microbiologia , Pneumonia por Pneumocystis/imunologia , Pneumonia por Pneumocystis/microbiologia , Resultado do TratamentoRESUMO
Patients with gliomas are at risk of cerebrovascular accidents (CVA) with potential consequences on survival, function, and local tumor control. Our objective was to provide information about CVA in patients with gliomas and to estimate survival in this group. We reviewed all adult glioma patients with ischemic CVA at the University of Texas-M.D. Anderson Cancer Center from 2003 through 2014. We extracted demographic, clinical, imaging, treatment and outcome data. We used descriptive summary data and estimated or compared survival rates where appropriate. 60 of 6500 patients (0.1%) with high-grade (HGG, n = 47) or low-grade glioma (LGG, n = 13) had ischemic CVA Thirty-two (53%) patients had postoperative strokes, and 20 (33%) had CVA after 2 weeks of surgery. Forty-one patients (68%) had gross total resection. For HGG and CVA, the poststroke median overall survival was 17 months versus 61 months in LGG and CVA (P = 0.03; hazard ratio (HR): 2.8; 95% CI 1.07-4.60). Survival stratified by modified Rankin Scale grade was significant (X(2) = 9.8, P = 0.007). Five patients received bevacizumab before stroke onset; none responded to antiangiogenic therapy. There was no stroke-related death. At our institution for 10 years, ischemic CVA in glioma patients was a rare complication, clearly associated in half of cases to surgery, and with a variable negative impact on performance status and neurologic function. In this group, patients with more neurological deficits lived less. The survival difference between and within subgroups was most likely due to tumor grade. More research is necessary to improve prevention of postoperative stroke in glioma patients.
Assuntos
Neoplasias Encefálicas/epidemiologia , Glioma/epidemiologia , Acidente Vascular Cerebral/epidemiologia , Idade de Início , Neoplasias Encefálicas/mortalidade , Neoplasias Encefálicas/terapia , Institutos de Câncer , Estudos de Coortes , Imagem de Difusão por Ressonância Magnética , Intervalo Livre de Doença , Feminino , Glioma/mortalidade , Glioma/terapia , Humanos , Estimativa de Kaplan-Meier , Imageamento por Ressonância Magnética , Masculino , Fatores de Risco , Índice de Gravidade de Doença , Fatores Sexuais , Acidente Vascular Cerebral/mortalidade , Acidente Vascular Cerebral/terapia , Texas/epidemiologia , Tomografia Computadorizada por Raios XAssuntos
Corticosteroides/uso terapêutico , Neoplasias Encefálicas/diagnóstico , Neoplasias Encefálicas/tratamento farmacológico , Neoplasias Neuroepiteliomatosas/diagnóstico , Neoplasias Neuroepiteliomatosas/tratamento farmacológico , Idoso , Neoplasias Encefálicas/fisiopatologia , Feminino , Humanos , Imageamento por Ressonância Magnética , Neoplasias Neuroepiteliomatosas/fisiopatologiaRESUMO
Sinking skin flap syndrome (SSFS) is a rare neurological complication in patients with traumatic haemorrhage, stroke or cerebral oedema who undergo decompressive craniectomy to relieve increased intracranial pressure. Hallmark of SSFS is the sinking of the scalp to a plane lower than the edges of the skull defect in the setting of neurological deterioration. Our objective is to report that SSFS can present after small craniotomy without cerebral cortex compression and to share our diagnostic/therapeutic approach. A 62-year-old woman with a glioblastoma developed SSFS after a small craniectomy and tumour resection without cerebral cortex compression but a decrease in the surgical cavity volume. Brain MRI showed decreased size of the surgical cavity. Interestingly, the patient also developed posterior reversible encephalopathy syndrome (PRES). This case highlights an atypical presentation of SSFS and the possible association with PRES. It also illustrates how an early cranioplasty can successfully reverse SSFS.
Assuntos
Transplante Ósseo/efeitos adversos , Neoplasias Encefálicas/cirurgia , Craniectomia Descompressiva/efeitos adversos , Glioblastoma/cirurgia , Síndrome da Leucoencefalopatia Posterior/etiologia , Transplante de Pele/efeitos adversos , Neoplasias Encefálicas/patologia , Craniectomia Descompressiva/métodos , Feminino , Seguimentos , Glioblastoma/patologia , Humanos , Imageamento por Ressonância Magnética/métodos , Síndrome da Leucoencefalopatia Posterior/diagnóstico , Complicações Pós-Operatórias/diagnóstico , Complicações Pós-Operatórias/cirurgia , Doenças Raras , Procedimentos de Cirurgia Plástica/métodos , Reoperação/métodos , Medição de Risco , Pele/fisiopatologia , Transplante de Pele/métodos , Síndrome , Resultado do TratamentoRESUMO
KEY CLINICAL MESSAGE: In immunocompromised patients, the pulmonary computed tomography halo sign is highly suggestive of angioinvasive aspergillosis. Early recognition may be life-saving.
Assuntos
Anticorpos Monoclonais Humanizados/efeitos adversos , Antineoplásicos/efeitos adversos , Doenças do Sistema Nervoso Central/induzido quimicamente , Idoso , Doenças do Sistema Nervoso Central/diagnóstico , Eletroencefalografia , Humanos , Imageamento por Ressonância Magnética , Masculino , Melanoma/tratamento farmacológicoRESUMO
Imaging has become a central part of the evaluation of lesions of the central nervous system. Despite patterns of the appearances of several types of central nervous system malignancies and improving resolution of imaging techniques, there are other processes that can display similar characteristics. Time and again, vascular, inflammatory, and vascular lesions will mimic a neoplastic process, requiring tissue diagnosis. With the introduction of advanced magnetic resonance imaging (MRI) and positron emission tomography (PET) imaging in the evaluation of the brain tumor, there has been improvement in determining whether a lesion is neoplastic, and further advances may lead to noninvasive pathological and molecular diagnoses.
Assuntos
Neoplasias do Sistema Nervoso Central/diagnóstico , Diagnóstico Diferencial , Humanos , Imageamento por Ressonância Magnética , Espectroscopia de Ressonância Magnética , Tomografia por Emissão de PósitronsRESUMO
BACKGROUND: Concurrent treatment with temozolomide and radiotherapy followed by maintenance temozolomide is the standard of care for patients with newly diagnosed glioblastoma. Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor A, is currently approved for recurrent glioblastoma. Whether the addition of bevacizumab would improve survival among patients with newly diagnosed glioblastoma is not known. METHODS: In this randomized, double-blind, placebo-controlled trial, we treated adults who had centrally confirmed glioblastoma with radiotherapy (60 Gy) and daily temozolomide. Treatment with bevacizumab or placebo began during week 4 of radiotherapy and was continued for up to 12 cycles of maintenance chemotherapy. At disease progression, the assigned treatment was revealed, and bevacizumab therapy could be initiated or continued. The trial was designed to detect a 25% reduction in the risk of death and a 30% reduction in the risk of progression or death, the two coprimary end points, with the addition of bevacizumab. RESULTS: A total of 978 patients were registered, and 637 underwent randomization. There was no significant difference in the duration of overall survival between the bevacizumab group and the placebo group (median, 15.7 and 16.1 months, respectively; hazard ratio for death in the bevacizumab group, 1.13). Progression-free survival was longer in the bevacizumab group (10.7 months vs. 7.3 months; hazard ratio for progression or death, 0.79). There were modest increases in rates of hypertension, thromboembolic events, intestinal perforation, and neutropenia in the bevacizumab group. Over time, an increased symptom burden, a worse quality of life, and a decline in neurocognitive function were more frequent in the bevacizumab group. CONCLUSIONS: First-line use of bevacizumab did not improve overall survival in patients with newly diagnosed glioblastoma. Progression-free survival was prolonged but did not reach the prespecified improvement target. (Funded by the National Cancer Institute; ClinicalTrials.gov number, NCT00884741.).
Assuntos
Inibidores da Angiogênese/uso terapêutico , Anticorpos Monoclonais Humanizados/uso terapêutico , Neoplasias Encefálicas/tratamento farmacológico , Glioblastoma/tratamento farmacológico , Adulto , Inibidores da Angiogênese/efeitos adversos , Anticorpos Monoclonais Humanizados/efeitos adversos , Bevacizumab , Neoplasias Encefálicas/mortalidade , Neoplasias Encefálicas/radioterapia , Terapia Combinada , Dacarbazina/efeitos adversos , Dacarbazina/análogos & derivados , Dacarbazina/uso terapêutico , Intervalo Livre de Doença , Método Duplo-Cego , Glioblastoma/mortalidade , Glioblastoma/radioterapia , Humanos , Modelos de Riscos Proporcionais , Análise de Sobrevida , TemozolomidaRESUMO
BACKGROUND: The etiology of encephalitis presents a diagnostic challenge and often remains a mystery. However, current technological advances using antibodies can enable a definitive diagnosis in cases that would previously have been suspected to be idiopathic or viral encephalitis. Our objective is to show that tonsil neuroendocrine carcinoma can present initially as limbic encephalitis mediated by N-type calcium channel antibodies and to highlight the diagnostic confusion before cancer detection. METHODS: We report a rare case of neuroendocrine cancer presenting as limbic encephalopathy, Lambert-Eaton myasthenic syndrome and neuropathy. The patient was diagnosed and treated at The University of Texas MD Anderson Cancer Center in November 2011. RESULTS: Paraneoplastic limbic encephalitis was diagnosed based on clinical presentation of seizures, short-term memory loss, retrograde amnesia, disorientation, distractibility, and abulia; on the exclusion of brain metastases, CNS infection, stroke, metabolic or nutritional deficits, or medication-related events; and on CSF results with inflammatory findings and an abnormal electroencephalography study that showed seizure activity in the left temporal lobe. Serum paraneoplastic panel was positive for P/Q-type calcium channel antibody and N-type calcium channel antibody. Magnetic resonance imaging of brain was unremarkable. CONCLUSION: This case highlights limbic encephalitis as an atypical presentation of neuroendocrine cancer. It also illustrates how treatment of the underlying cancer can reverse limbic encephalitis and Lambert-Eaton myasthenic syndrome in a neuroendocrine carcinoma patient even before the paraneoplastic panel becomes negative.